Verdad Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Verdad Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.52M	Buy	+68,290	New	+$1.63M	1.71%	10

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Verdad Advisers's ACAD Position: Q1 2026 in Review

Verdad Advisers opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 68,290 shares worth $1.52M. The stake represents 1.71% of the portfolio and ranks #10 among its holdings.

340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

Verdad Advisers held 68,290 shares of Acadia Pharmaceuticals worth $1.52M as of Q1 2026.
Acadia Pharmaceuticals was a new Verdad Advisers position in Q1 2026.
Acadia Pharmaceuticals made up 1.71% of Verdad Advisers's portfolio in Q1 2026, its #10 holding.
340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Verdad Advisers's 13F filing for Q1 2026, filed 15 May 2026.